CCM
GLUE icon

CAAS Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

CAAS Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$1.11M – 934
2021
Q3 		$1.11M Hold
50,000
– – 0.02% 464
2021
Q2 		$1.14M Buy
+50,000
New +$1.02M 0.02% 516

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's GLUE Position: Q4 2021 in Review

CAAS Capital Management sold out of Monte Rosa Therapeutics (GLUE) in Q4 2021, closing a stake of 50,000 shares — an estimated $1.11M sold.

CAAS Capital Management first reported a position in GLUE in Q2 2021 and held it in 2 quarters. The position peaked at $1.14M in Q2 2021. 53 funds tracked by Wall St. Rank hold GLUE as of Q4 2021.

  • CAAS Capital Management reported no remaining Monte Rosa Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 50,000 Monte Rosa Therapeutics shares in Q4 2021, an estimated $1.11M.
  • CAAS Capital Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Monte Rosa Therapeutics position peaked at $1.14M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.